Related Experiment Video
Updated: Jul 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic
Austin Duffy1, Jinru Shia, Fidel David Huitzil-Melendez
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
A 32-year-old Asian male presented with perforated sigmoid colorectal cancer (CRC) and large, unresectable hepatic metastasis. After surgery for his primary tumor, he received 6 months of FOLFOX (5-fluorouracil/leucovorin/ oxaliplatin) plus bevacizumab and achieved a partial response. He underwent hepatic metastasectomy and was found to have had a complete pathologic response (pCR) to treatment. The literature regarding pCR with chemotherapy in CRC and the implications for further management is discussed herein.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
